

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Suzhou Basecare Medical Corporation Limited**

**蘇州貝康醫療股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2170)**

### **INSIDE INFORMATION ANNOUNCEMENT**

### **APPROVAL BY THE CSRC OF THE APPLICATION IN RESPECT OF H SHARE FULL CIRCULATION PROGRAMME OF THE COMPANY**

This announcement is made by Suzhou Basecare Medical Corporation Limited (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated August 20, 2021 in relation to proposed participation in the H share full circulation programme by the Company.

The board of directors of the Company (the “**Board**”) is pleased to announce that on February 24, 2022, the Company received the official approval (the “**Approval**”) from the China Securities Regulatory Commission (the “**CSRC**”) regarding the implementation of the H share full circulation programme of the Company, pursuant to which up to 192,592,582 unlisted shares can be converted into H shares of the Company and their listing thereof on the Stock Exchange (the “**Conversion and Listing**”). Once converted, the total number of H shares listed and circulated on the Stock Exchange will be up to 273,526,000, which represent 100% of total shares outstanding of the Company. The Approval shall be valid for 12 months from January 24, 2022.

The Company will make further announcements on the progress of the Conversion and Listing in compliance with the Listing Rules and other applicable rules. Completion of the Conversion and Listing is subject to the performance of other relevant procedures required by the CSRC, the Stock Exchange and other onshore and offshore regulatory authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board  
**Suzhou Basecare Medical Corporation Limited**  
**Dr. Liang Bo**  
*Chairman and General Manager*

Suzhou, PRC, February 24, 2022

*As of the date of this announcement, the Board comprises Dr. LIANG Bo, Mr. KONG Lingyin and Mr. RUI Maoshe as executive Directors; Mr. XU Wenbo, Mr. ZHANG Jiecheng and Mr. WANG Weipeng as non-executive Directors; and Dr. KANG Xixiong, Dr. HUANG Taosheng and Mr. CHAU Kwok Keung as independent non-executive Directors.*